CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 116 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,868,446 | +746.4% | 62,826 | +357.1% | 0.00% | – |
| Q2 2023 | $220,745 | 0.0% | 13,745 | 0.0% | 0.00% | – |
| Q1 2023 | $220,745 | -53.7% | 13,745 | -47.3% | 0.00% | – |
| Q4 2022 | $477,008 | -99.9% | 26,066 | 0.0% | 0.00% | – |
| Q3 2022 | $511,936,000 | +99.7% | 26,066 | +89.6% | 0.00% | – |
| Q2 2022 | $256,344,000 | -22.3% | 13,745 | -8.5% | 0.00% | – |
| Q1 2022 | $329,711,000 | -49.5% | 15,021 | -34.6% | 0.00% | – |
| Q4 2021 | $652,634,000 | +92.1% | 22,972 | +42.3% | 0.00% | – |
| Q3 2021 | $339,747,000 | +11.7% | 16,140 | 0.0% | 0.00% | – |
| Q2 2021 | $304,239,000 | +37.3% | 16,140 | +11.3% | 0.00% | – |
| Q1 2021 | $221,606,000 | +8.3% | 14,503 | 0.0% | 0.00% | – |
| Q4 2020 | $204,637,000 | +24.3% | 14,503 | +38.1% | 0.00% | – |
| Q3 2020 | $164,582,000 | -71.8% | 10,503 | -68.4% | 0.00% | – |
| Q2 2020 | $582,610,000 | – | 33,254 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |